1. Home
  2. GCDT vs ACXP Comparison

GCDT vs ACXP Comparison

Compare GCDT & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GCDT

Green Circle Decarbonize Technology Limited Ordinary Shares

N/A

Current Price

$0.37

Market Cap

5.3M

Sector

Industrials

ML Signal

N/A

Logo Acurx Pharmaceuticals Inc.

ACXP

Acurx Pharmaceuticals Inc.

HOLD

Current Price

$1.41

Market Cap

6.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GCDT
ACXP
Founded
1992
2017
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.3M
6.2M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
GCDT
ACXP
Price
$0.37
$1.41
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$95.50
AVG Volume (30 Days)
286.2K
176.3K
Earning Date
05-16-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.33
$1.31
52 Week High
$5.32
$8.34

Technical Indicators

Market Signals
Indicator
GCDT
ACXP
Relative Strength Index (RSI) 40.06 44.95
Support Level $0.33 $1.35
Resistance Level $0.47 $1.77
Average True Range (ATR) 0.05 0.10
MACD -0.00 -0.00
Stochastic Oscillator 3.79 6.93

Price Performance

Historical Comparison
GCDT
ACXP

About GCDT Green Circle Decarbonize Technology Limited Ordinary Shares

Green Circle Decarbonize Technology Ltd is a company which provides advanced energy saving solutions supported by proprietary phase change thermal energy storage materials and thermal engineering services. As an advocate of decarbonization, the Company designs, develops and provides customized energy saving solutions that bring considerable economic benefits to our clients and reduce carbon emissions for a sustainable future.

About ACXP Acurx Pharmaceuticals Inc.

Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.

Share on Social Networks: